13 EMERGED · WAVE 13 · D2-HG AXIS
IDH-mutant GBM: ivosidenib/enasidenib → D2-HG inhibition → BBB restoration + P-52 preservation. Routes 1+3+5 CLOSED.
IDH-wildtype (90% cases): EGFR inhibitor combo → partial BBB + P-52 hold. Routes 2+4 PARTIAL.
⚠ 6th route OPEN: IDH-wildtype simultaneous BBB+CAR-T — no clean solve yet. Filed: S006-wt. Next wave seed.